SMStacey Markovic

Stacey Markovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stacey Markovic has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Performance of computer vision in vivo flow cytometry with low fluorescence contrast

    by Stacey Markovic, Siyuan Li, Mark J. Niedre

    Detection and enumeration of circulating cells in the bloodstream of small animals are important in many areas of preclinical biomedical research, including cancer metastasis, immunology, and reproductive medicine. Optical in vivo flow cytometry (IVFC) represents a class of technologies that allow noninvasive and continuous enumeration of circulating cells without drawing blood samples. We recently developed a technique termed computer vision in vivo flow cytometry (CV-IVFC) that uses a high-sensitivity fluorescence camera and an automated computer vision algorithm to interrogate relatively large circulating blood volumes in the ear of a mouse. We detected circulating cells at concentrations as low as 20  cells/mL. In the present work, we characterized the performance of CV-IVFC with low-contrast imaging conditions with (1) weak cell fluorescent labeling using cell-simulating fluorescent microspheres with varying brightness and (2) high background tissue autofluorescence by varying autofluorescence properties of optical phantoms. Our analysis indicates that CV-IVFC can robustly track and enumerate circulating cells with at least 50% sensitivity even in conditions with two orders of magnitude degraded contrast than our previous in vivo work. These results support the significant potential utility of CV-IVFC in a wide range of in vivo biological models.


  • Open Access

    Nanoparticle-Based Brachytherapy Spacers for Delivery of Localized Combined Chemoradiation Therapy

    by Rajiv Kumar, Jodi Belz, Stacey Markovic, Tej Jadhav, William Fowle, Mark Niedre, Robert Cormack, Mike G. Makrigiorgos, Srinivas Sridhar


  • Toward lower contrast computer vision in vivo flow cytometry

    by Stacey Markovic, Siyuan Li, Tianxue Zhang, Mark Niedre

    There are many applications in biomedical research where detection and enumeration of circulating cells (CCs) is important. Existing techniques involve drawing and enriching blood samples and analyzing them ex vivo. More recently, small animal “in vivo flow cytometry” (IVFC) techniques have been developed, where fluorescently-labeled cells flowing through small arterioles (ear, retina) are detected and counted. We recently developed a new high-sensitivity IVFC technique termed “Computer Vision(CV)-IVFC”. Here, large circulating blood volumes were monitored in the ears of mice with a wide-field video-rate near-infrared (NIR) fluorescent camera. Cells were labeled with a membrane dye and were detected and tracked in noisy image sequences. This technique allowed enumeration of CCs in vivo with overall sensitivity better than 10 cells/mL. However, an ongoing area of interest in our lab is optimization of the system for lower-contrast imaging conditions, e.g. when CCs are weakly labeled, or in the case higher background autofluorescence with visible dyes. To this end, we developed a new optical flow phantom model to control autofluorescence intensity and physical structure to better mimic conditions observed in mice. We acquired image sequences from a series of phantoms with varying levels of contrast and analyzed the distribution of pixel intensities, and showed that we could generate similar conditions to those in vivo. We characterized the performance of our CV-IVFC algorithm in these phantoms with respect to sensitivity and false-alarm rates. Use of this phantom model in optimization of the instrument and algorithm under lower-contrast conditions is the subject of ongoing work in our lab.


  • Abstract A82: Localized tumor delivery of radiosensitizers and chemotherapeutics using ‘INCeRT’ implants.

    by Rajiv Kumar, Jodi E. Belz, Stacey Markovic, Houari Korideck, Wilfred F. Ngwa, Mark Niedre, Ross I. Berbeco, Robert Cormack, Mike G. Makrigiorgos, Srinivas Sridhar

    In cancer therapy, effective delivery of the therapeutic plays a critical role in determining the success of the treatment planning system. In last decade, there is a major thrust in developing novel nanoparticles based delivery systems to improve the therapeutic benefits in cancer. An efficient delivery system should be able to target the diseased site with minimal systemic toxicity and a slow sustained release of the drug. Here, we have fabricated a nanoparticles based smart ‘INCeRT’ (Implantable Nanoplatform for Chemo-Radiation Therapy) implant for localized delivery of radiosensitizing nanoparticles/ drugs in prostate cancer in conjunction with brachytherapy. These implants are physically similar to the clinically used brachytherapy spacers but have the added capability of imaging and local drug delivery. We have fabricated INCeRT spacers with biocompatible and biodegradable polymer, PLGA (poly-(lactide-co-glycolide)) impregnated with nanoparticles encapsulating imaging probe (Cyanine 7.5) and chemotherapeutic drug, docetaxel (DTX). Using a similar approach, we have also fabricated PLGA spacers impregnated with high Z (atomic number) gold nanoparticles (Hi-Z-CuRE: High Z-Customizable Radiotherapy Enhancement) for effectively boosting the radiation dose locally. The morphology, composition and nanoparticle's distribution inside the spacers was studied by SEM (scanning electron microscopy) and EDS (Energy-dispersive X-ray spectroscopy). Further, preliminary in vivo imaging experiments with subcutaneous prostate cancer tumored mice implanted with INCeRT spacers showed a size dependent diffusion of nanoparticles from the spacers in the tumor matrix. Also, from in vivo therapeutic studies with these spacers showed a sustained and slow release of the DTX from the spacers and showed a better response in suppressing the tumor as opposed control mice with saline injections. Further experiments for studying the combined chemo-radiation therapy are underway. This new treatment approach would be of crucial benefit for patients with local relapse who require salvage radiotherapy but have reached their radiotherapy normal tissue dose limits. This work was supported partially by NSF-DGE-0965843, HHS/1U54CA151881 CORE1, 1R03 CA164645-01 and a seed grant from the BWH Biomedical Research Institute. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A82. Citation Format: Rajiv Kumar, Jodi E. Belz, Stacey Markovic, Houari Korideck, Wilfred F. Ngwa, Mark Niedre, Ross I. Berbeco, Robert Cormack, Mike G. Makrigiorgos, Srinivas Sridhar. Localized tumor delivery of radiosensitizers and chemotherapeutics using ‘INCeRT’ implants. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A82.